Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24328040 | 0.81 | KDM4E (0.31) | KDM4EMEN1KMT2A | |
| SCHEMBL21670414 | 0.81 | KDM4E (0.31) | KDM4EMEN1KMT2A | |
| SCHEMBL21670416 | 0.81 | KDM4E (0.31) | KDM4EMEN1KMT2A | |
| SCHEMBL6115468 | 0.71 | MEN1 (0.40) | SMARCA4KDM4EMEN1KMT2APBRM1 | |
| SCHEMBL6115465 | 0.71 | MEN1 (0.40) | SMARCA4KDM4EMEN1KMT2APBRM1 | |
| SCHEMBL13100853 | 0.70 | MEN1 (0.44) | SMARCA4KDM4EMEN1KMT2A | |
| SCHEMBL10191696 | 0.70 | KDM4E (0.39) | SMARCA4KDM4EMEN1KMT2A | |
| SCHEMBL25626428 | 0.69 | KDM4E (0.32) | SMARCA4KDM4EMEN1KMT2A | |
| SCHEMBL24329220 | 0.67 | SMARCA4 (0.32) | SMARCA4PBRM1 | |
| SCHEMBL7241284 | 0.67 | KMT2A (0.49) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022042676-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | FLT3, ABL1, FLI1 | DRD4 4410/4885SMARCA4 1473/4885KDM4E 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.